The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer

NCT07704645 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Resectable Non-small Cell Lung Cancer

Interventions

DRUG: Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection
DRUG: Adebrelimab Injection combined with HRS-7058 Capsule

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.